Founded in 2016, Resolve Molecular Diagnostics (RMDx) has been an innovator in genetic testing. RMDx is proud to expand its advanced lab capabilities and services to include the new Elecsys® Anti-SARS-CoV-2 antibody test. Our dedicated team and instruments ensure that healthcare providers, employers, corporate wellness, and occupational medicine entities have access to the greatest accuracy, highest precision and fastest results for COVID-19 testing.
- Elecsys® Anti-SARS-CoV-2 antibody test uses a blood draw to detect antibodies made against the SARS-CoV-2 virus to identify whether a person has (or previously had) COVID-19.
- Accurate —99.81% specificity achieved through the testing of 5,272 samples and 100% sensitivity ≥ 14 days after PCR confirmation
- Precise —No cross reactivity found in 80 samples from individuals with past infection to common cold and other coronaviruses
- Scalable — can screen hundreds of thousands of subjects easily.
Resolve Molecular Diagnostics now provides Elecsys® Anti-SARS-CoV-2 (COVID-19/coronavirus) antibody testing developed by Roche Diagnositcs.
The Elecsys® Anti-SARS-CoV-2
The Elecsys® Anti-SARS-CoV-2 assay is unique among the currently commercially available immunoassays because it detects high-affinity antibodies to SARS-CoV-2. The assay relies on a double antigen sandwich (DAGS) format that enriches detection of higher affinity antibodies, which are more likely to be specific for SARS-CoV-2. Although this assay format is agnostic to the antibody isotype and in principle can detect high affinity antibodies of all isotypes, it preferentially detects IgG antibodies since these are most likely to evolve to become high affinity. The nucleocapsid antigen is abundantly expressed and is a useful target for sensitive detection of virus-specific antibodies. These features provide an optimal combination of high specificity and sensitivity for the detection of immune exposure to SARS-CoV-2.